115 related articles for article (PubMed ID: 26256743)
21. Use of healthy volunteers drives clinical oncology drug development decision making.
Iwamoto M; Iannone R; Wagner JA
Clin Pharmacol Ther; 2012 Nov; 92(5):571-4. PubMed ID: 23010649
[No Abstract] [Full Text] [Related]
22. Phase 0 trials for anticancer drug development.
Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
[No Abstract] [Full Text] [Related]
23. Is target validation all we need?
Frigault MM; Barrett JC
Curr Opin Pharmacol; 2014 Aug; 17():81-6. PubMed ID: 25261632
[TBL] [Abstract][Full Text] [Related]
24. Drug transport and metabolism of novel anticancer drugs.
Peters GJ; Honeywell RJ
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):661-3. PubMed ID: 25940025
[No Abstract] [Full Text] [Related]
25. The potential successes and challenges of targeted anticancer therapies.
Keefe D; Stringer A
Curr Opin Support Palliat Care; 2010 Mar; 4(1):16-8. PubMed ID: 20009759
[No Abstract] [Full Text] [Related]
26. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
27. New class of kinase inhibitors poised to join the anticancer arsenal.
Opar A
Nat Rev Drug Discov; 2012 Nov; 11(11):819-20. PubMed ID: 23123929
[No Abstract] [Full Text] [Related]
28. Anticancer therapy-induced adverse events: practicing damage control.
Lacouture ME; Lenihan D; Wu S
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S1-3. PubMed ID: 22409299
[No Abstract] [Full Text] [Related]
29. Measurement of success: parameters of efficacy.
de Mulder PH
Br J Cancer Suppl; 1992 Dec; 19():S68. PubMed ID: 1467205
[No Abstract] [Full Text] [Related]
30. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
31. Metabolomics in cancer: a bench-to-bedside intersection.
Claudino WM; Goncalves PH; di Leo A; Philip PA; Sarkar FH
Crit Rev Oncol Hematol; 2012 Oct; 84(1):1-7. PubMed ID: 22429650
[TBL] [Abstract][Full Text] [Related]
32. Standard Operating Procedures for clinical trials of the CESAR Central European Society for Anticancer Drug Research--EWIV. Preface.
Gastl G; Dittrich C
Onkologie; 2003 Oct; 26 Suppl 6():IX. PubMed ID: 23570176
[No Abstract] [Full Text] [Related]
33. Forty years of translational cancer research.
Hait WN
Cancer Discov; 2011 Oct; 1(5):383-90. PubMed ID: 22586630
[TBL] [Abstract][Full Text] [Related]
34. kConFab: a familial breast cancer consortium facilitating research and translational oncology.
Thorne H; Mitchell G; Fox S;
J Natl Cancer Inst Monogr; 2011; 2011(43):79-81. PubMed ID: 22043047
[TBL] [Abstract][Full Text] [Related]
35. [Collaboration between academia for the development of translational research].
Nagamura F
Nihon Yakurigaku Zasshi; 2015 Apr; 145(4):211-5. PubMed ID: 25864833
[No Abstract] [Full Text] [Related]
36. Antiemetic study design: a discussion of Dr Olver's paper.
Groshen S
Br J Cancer Suppl; 1992 Dec; 19():S35-7. PubMed ID: 1467199
[No Abstract] [Full Text] [Related]
37. Comment on "Translational applications of flow cytometry in clinical practice".
Monneret G; Venet F
J Immunol; 2012 Aug; 189(3):1099. PubMed ID: 22815377
[No Abstract] [Full Text] [Related]
38. Power of rare diseases: found in translation.
Fishman MC
Sci Transl Med; 2013 Sep; 5(201):201ps11. PubMed ID: 24005157
[TBL] [Abstract][Full Text] [Related]
39. [Current status and issues in early & exploratory oncology clinical trials in Japan].
Ohtsu A
Nihon Rinsho; 2015 Feb; 73 Suppl 2():23-9. PubMed ID: 25831719
[No Abstract] [Full Text] [Related]
40. Drug trials in pediatric oncology: a multi-facetted problem.
Boos J
Int J Clin Pharmacol Ther; 1998 Nov; 36(11):613-20. PubMed ID: 9849753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
